tiprankstipranks
Advertisement
Advertisement

ASND Stock Latest News

BMO starts Ascendis at Outperform on further platform growth
The FlyBMO starts Ascendis at Outperform on further platform growth
5d ago
ASND
Ascendis Pharma initiated with an Outperform at BMO Capital
PremiumThe Fly
Ascendis Pharma initiated with an Outperform at BMO Capital
5d ago
ASND
Ascendis Pharma reports Q2 EPS 90c, consensus 77c
PremiumThe Fly
Ascendis Pharma reports Q2 EPS 90c, consensus 77c
6d ago
ASND
Ascendis Pharma price target lowered to $329 from $345 at Barclays
PremiumThe Fly
Ascendis Pharma price target lowered to $329 from $345 at Barclays
7d ago
ASND
Ascendis Pharma price target raised to $341 from $325 at TD Cowen
PremiumThe Fly
Ascendis Pharma price target raised to $341 from $325 at TD Cowen
7d ago
ASND
Ascendis Pharma price target raised to $290 from $280 at RBC Capital
PremiumThe FlyAscendis Pharma price target raised to $290 from $280 at RBC Capital
7d ago
ASND
Yun Zhong Reiterates Buy on Ascendis, Citing Strong Product Momentum and Long-Term Growth with Unchanged $327 Price Target
Premium
Ratings
Yun Zhong Reiterates Buy on Ascendis, Citing Strong Product Momentum and Long-Term Growth with Unchanged $327 Price Target
10d ago
ASND
Ascendis Pharma Doubles Q2 Revenue as Rare Disease Portfolio Scales and Debt Retired
Premium
Company Announcements
Ascendis Pharma Doubles Q2 Revenue as Rare Disease Portfolio Scales and Debt Retired
10d ago
6K
ASND
Ascendis Pharma Files Strong Interim Q2 2026 Results on Form 6-K
PremiumCompany Announcements
Ascendis Pharma Files Strong Interim Q2 2026 Results on Form 6-K
10d ago
6K
ASND
Ascendis Pharma Grants New Employee Warrants as Part of Updated Capital Structure
PremiumCompany Announcements
Ascendis Pharma Grants New Employee Warrants as Part of Updated Capital Structure
11d ago
6K
ASND
Ascendis Pharma A/S (ASND) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Ascendis Pharma A/S (ASND) Q2 Earnings Cheat Sheet
12d ago
ASND
Ascendis Pharma Posts Strong Achondroplasia Data and Early U.S. YUVIWEL Uptake
PremiumCompany Announcements
Ascendis Pharma Posts Strong Achondroplasia Data and Early U.S. YUVIWEL Uptake
17d ago
6K
ASND
Is ASND a Buy, Before Earnings?
PremiumPre-EarningsIs ASND a Buy, Before Earnings?
19d ago
ASND
Ascendis Pharma Expands Yorvipath Into Adolescents, Raising Long-Term Growth Hopes
Premium
Company Announcements
Ascendis Pharma Expands Yorvipath Into Adolescents, Raising Long-Term Growth Hopes
26d ago
ASND
Ascendis Pharma price target raised to $275 from $256 at Morgan Stanley
Premium
The Fly
Ascendis Pharma price target raised to $275 from $256 at Morgan Stanley
1M ago
ASND
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
PremiumThe Fly
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
2M ago
ASND
BCRX
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
PremiumThe Fly
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
2M ago
ASND
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia
2M ago
6K
ASND
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial
PremiumThe Fly
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial
2M ago
ASND
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital
PremiumCompany AnnouncementsAscendis Pharma Closes Warrant Exercise Window, Expands Share Capital
2M ago
6K
ASND
Ascendis Pharma added to multiple Russell U.S. Indexes
Premium
The Fly
Ascendis Pharma added to multiple Russell U.S. Indexes
2M ago
ASND
Ascendis Pharma Monetizes FDA Priority Review Voucher for $187.5 Million
Premium
Company Announcements
Ascendis Pharma Monetizes FDA Priority Review Voucher for $187.5 Million
2M ago
6K
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >